CoChat

Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times

Open access
Mattke, Soeren, Cho, Sang Kyu, Bittner, Tobias, Hlávka, Jakub, Hanson, Mark · 2020 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Cited by 70

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Concerns have been raised about the limited health system capacity for identification of patients who are eligible for a disease-modifying Alzheimer's treatment (DMT). Blood-based biomarker (BBBM) tests are a promising tool to improve triaging at the primary care level. We projected their impact on cost of and wait times during the diagnostic process. METHODS: We compare four scenarios for triaging patients at the primary care level from the perspective of the U.S. health care system: (1) cognitive test only (Mini Mental State Examination [MMSE]), (2) BBBM test only, (3) MMSE followed by BBBM if positive, and (4) BBBM followed by MMSE if positive. RESULTS: Referring patients to dementa specialists based on MMSE or BBBM results alone would continuously require more specialist appointments than projected to be available until 2050. Combining MMSE and BBBM would eliminate wait lists after the first 3 years and reduce average annual cost by $400 to 700 million, while increasing correctly identified cases by about 120,000 per year. DISCUSSION: The combination BBBM with MMSE is projected to increase the efficiency and value of the triage process for DMT eligibility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dad2.12081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 70

Metadata

Authors
Mattke, S., Cho, S. K., Bittner, T., Hlávka, J., & Hanson, M.
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2020-01
Volume
12
Issue
1
Pages
e12081-e12081
ISSN
2352-8729 (ISSN-L)
OpenAlex
W3054673551
Cited by
70
References
14
FWCI
5.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times. https://app.cochat.ai/papers/10.1002/dad2.12081
The paper
Mattke, S., Cho, S. K., Bittner, T., Hlávka, J., & Hanson, M. (2020). Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1002/dad2.12081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.